Clinical Trial Update: A Continued Access Protocol to Provide Xolair to Patients With Severe Allergic Asthma [Phase 3]

View source ↗

Summary

This document reports the completion of a continued access protocol for Xolair (omalizumab) in patients with severe allergic asthma in Phase 3.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Xolair (omalizumab)

Snippet

Sponsor: Genentech, Inc. | Conditions: Asthma | Phase 3 | Status: COMPLETED